 Landos Biopharma Inc NASDAQ: LABP and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China mainland China, Hong Kong, Taiwan, and Macau and select Asian markets. Omilancor is a novel, oral, gut-restricted LANCL2 agonist in development for the treatment of ulcerative colitis UC, Crohns disease CD, and Eosinophilic Esophagitis EoE. 